Generic Medicine Info
Indications and Dosage
Cardiac arrhythmias, Heart failure
Adult: Up to 1.6 mg may be given as a single dose or in divided doses. Maintenance treatment with an orally administered cardiac glycoside may be started within 12 hr of parenteral digitalisation with deslanoside.
Wolff-Parkinson-White syndrome; hypertrophic obstructive cardiomyopathy.
Special Precautions
CV disease; partial heart block, sinus node disorders, acute myocarditis, acute MI, advanced heart failure, severe pulmonary disease, thyroid dysfunction, hypokalaemia, hypomagnesaemia, hypercalcaemia, hypoxia, hypothyroidism, impaired renal function, elderly, premature infants. Maintain heart rate >60 beats/min. withdraw 1-2 days before undergoing cardioversion. Not an appropriate form of therapy for any ventricular arrhythmia. Pregnancy.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, color vision may be affected, gynecomastia, vasoconstriction, and transient hypotension (rapid IV inj), local irritation (SC/IM), hypokalaemia.
Potentially Fatal: Heart failure, supraventricular or ventricular arrhythmias, defects of conduction.
Drug Interactions
Thiazides, loop diuretics; corticosteroids; β2-agonist, amphotericin B; sodium polystyrene sulfonate; carbenoxolone; IV admin of calcium salts; quinidine; amiodarone; propafenone; other antiarrhythmics; β-blockers; calcium-channel blockers.
Mechanism of Action: Deslanoside is a cardiac glycoside with positive inotropic activity.
Onset: 5-10 min.
Duration: 2-5 days.
Absorption: Effects occur within 5-10 min after IV admin.
Excretion: Half-life: About 33 hr.
MIMS Class
Cardiac Drugs
Disclaimer: This information is independently developed by MIMS based on Deslanoside from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in